The FDA is poised to be the primary regulatory body governing and setting policy for consumer sales of CBD in the USA. The “wild card” is what, if anything, it will do about products containing hemp extract with CBD.
By any measure, it is wrong to force medical marijuana patients to choose between employment and taking the medicine they need to live balanced and productive lives.
2020 will be a historic and transformative year for cannabis, particularly for hemp and CBD. Here are my top 5 predictions.
As an advisory board member and legal author for the American Journal of Endocannabinoid Medicine, I am pleased to offer a copy of the most recent edition in PDF form at the bottom of this blog. Immediately below is my article.
As the hemp flower matures and the CBD increases, the total THC also increases, both predictably and consistently (0.1% increase in Total THC for every 2% increase in Total CBD) across the more than 50 strains tested.
I was recently asked by my friends at Darling Hemp to participate in a video they created to highlight some of the most important issues that the Rule raises.
Considering the large and growing number of hemp and CBD companies doing business in the US right now, the companies that received warning letters might rightly consider themselves unlucky.
Although the DEA announcement appears to be a step in the right direction, many in the cannabis industry contend that the announcement is a stalling tactic.
This historic Act could change the face of the cannabis industry as we know it. If passed, it would affect countless people whose lives have been ruined by the archaic and prohibitionist approach to non-violent cannabis offenses.
In this article I will discuss the Rule’s impact on hemp that was grown and harvested in 2019, much of which is currently on the market.